Copyright
©The Author(s) 2019.
World J Gastroenterol. Feb 21, 2019; 25(7): 808-823
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.808
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.808
Figure 8 Effect of RAS pathway protein expression on progression-free survival and overall survival in patients with stage II/III colorectal cancer.
A-H: Effects of KRAS (A and B), BRAF (C and D), MEK (E and F), and ERK (G and H) protein expression on progression-free survival (A, C, E, and G) and overall survival (B, D, F, and H). PFS: Progression-free survival; OS: Overall survival.
- Citation: Wan XB, Wang AQ, Cao J, Dong ZC, Li N, Yang S, Sun MM, Li Z, Luo SX. Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer. World J Gastroenterol 2019; 25(7): 808-823
- URL: https://www.wjgnet.com/1007-9327/full/v25/i7/808.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i7.808